SCHEMBL5475184

SCHEMBL5475184

N#CC1(c2ccc([N+](=O)[O-])cc2)CCS(=O)(=O)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SCD O00767 1/20 0.42
▸ PGR P06401 1/20 0.40
▸ NPSR1 Q6W5P4 2/20 0.39
▸ MAPT P10636 2/20 0.39
▸ HTR1E P28566 1/20 0.39
▸ S1PR3 Q99500 1/20 0.39
▸ ALDH1A1 P00352 3/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ NPC1 O15118 2/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ OPRM1 P35372 3/20 0.38
▸ SIRT6 Q8N6T7 1/20 0.36
▸ HSP90AA1 P07900 1/20 0.36
▸ USP2 O75604 1/20 0.36
▸ USP18 Q9UMW8 1/20 0.36
▸ UCHL5 Q9Y5K5 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2814643 0.87 ALDH1A1 (0.44) SCDPGRNPSR1MAPTHTR1E
SCHEMBL1769324 0.87 PGR (0.46) SCDPGRNPSR1MAPTALDH1A1
SCHEMBL2815633 0.86 ALDH1A1 (0.43) SCDPGRNPSR1MAPTHTR1E
SCHEMBL3047350 0.84 PGR (0.43) SCDPGRNPSR1MAPTHTR1E
SCHEMBL3897910 0.80 L3MBTL1 (0.44) SCDPGRMAPTALDH1A1NPC1
SCHEMBL2876866 0.80 PDE4A (0.41) SCDPGRNPSR1MAPTALDH1A1
SCHEMBL521393 0.80 ADRB1 (0.44) SCDPGROPRM1SIRT6
SCHEMBL23727719 0.78 NPSR1 (0.45) NPSR1MAPTHTR1ES1PR3ALDH1A1
SCHEMBL5468463 0.78 OPRM1 (0.41) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL14385151 0.76 HSP90AA1 (0.42) NPSR1MAPTHTR1ES1PR3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9394289-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2016-07-19 — — US disclosed
US-9394289-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2016-07-19 — — US disclosed
US-9394289-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2016-07-19 — — US disclosed
EP-2016070-B1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2016-01-13 — — EP disclosed
US-20140378457-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2014-12-25 — — US disclosed
US-20140378457-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2014-12-25 — — US disclosed
US-20140378457-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2014-12-25 — — US disclosed
US-8859602-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2014-10-14 — — US disclosed
US-8859602-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2014-10-14 — — US disclosed
US-8859602-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2014-10-14 — — US disclosed
WO-2007124319-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-01 — — WO disclosed
US-20070249680-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2007-10-25 — — US disclosed
US-20070249680-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2007-10-25 — — US disclosed
US-20070249680-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2007-10-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140378457-A1 INHIBITORS OF C-FMS KINASE MUSK, FRK, FES SCD 4795/4885PGR 1322/4885NPSR1 398/4885
US-20070249680-A1 INHIBITORS OF C-FMS KINASE MUSK, FRK, FES SCD 4795/4885PGR 1322/4885NPSR1 398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback